澳大利亚轮状病毒疫苗有效性病例对照研究
该研究采用回顾性病例对照设计,评估2009—2011年西澳大利亚5岁以下儿童中RV1和RV5对实验室确诊并上报的轮状病毒感染的有效性。共纳入282例病例和883例对照,结果显示全程接种调整VE为72%(95%CI:56-82),部分接种为71%(95%CI:50-84)。
要点
- RV1和RV5全程接种对实验室确诊轮状病毒感染均有良好保护。
- RV5三剂全程VE为82%(95%CI:59-92),RV1两剂全程VE为73%(95%CI:55-83)。
- 即使未完成全程接种,部分接种也提供较好保护(VE 71%)。
核心结论
- RV1和RV5均能有效预防5岁以下儿童实验室确诊并上报的轮状病毒感染。
- 即使接种程序不完整,仍可提供良好保护。
研究设计与样本
- 回顾性病例对照研究,病例为2009—2011年西澳大利亚5岁以下疫苗适龄儿童中实验室确诊并上报的轮状病毒感染病例。
- 对照为同期疫苗适龄儿童中上报的弯曲杆菌或沙门菌感染病例。
- 共纳入282例病例和883例对照,免疫状态取自基于人群的免疫登记系统。
主要发现
- 全程接种任一种轮状病毒疫苗的调整VE为72%(95%CI:56-82)。
- 部分接种(RV1一剂或RV5一至两剂)的调整VE为71%(95%CI:50-84)。
- RV5三剂全程VE为82%(95%CI:59-92),RV1两剂全程VE为73%(95%CI:55-83)。
关键数值与推荐
- 全程接种任一种疫苗调整VE为72%(95%CI:56-82)。
- 部分接种调整VE为71%(95%CI:50-84)。
- RV5三剂全程VE为82%(95%CI:59-92)。
- RV1两剂全程VE为73%(95%CI:55-83)。
临床怎么用
- 支持在5岁以下儿童中按程序接种轮状病毒疫苗以预防实验室确诊感染。
- 未完成全程接种的儿童仍可获得一定保护,但应尽量完成全程接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Two rotavirus vaccines (RV1 and RV5) were included in the publicly funded National Immunisation Program in Australia from July 2007. The programme in Western Australia initially provided RV1 (at ages 2 and 4 months) and then switched to RV5 (at ages 2, 4 and 6 months) from July 2009. This retrospective case-control study was conducted to assess the effectiveness of rotavirus vaccine against laboratory confirmed and notified cases of rotavirus infection among children aged <5 years. METHODS: Case-subjects were identified as vaccine-eligible children (born from 1 May 2007) who were notified as having rotavirus infection during the period 2009-2011. The control group was vaccine-eligible children notified as having Campylobacter or Salmonella infection during the same period. Individual rotavirus immunisation status was ascertained from a population-based immunisation register. Full-dose and partial-dose vaccine effectiveness (VE) were calculated for both vaccines using the adjusted odds ratio (OR) of vaccination for cases versus controls (VE = (1 - OR)*100%). RESULTS: Overall, 282 cases and 883 controls were included. The adjusted VE for a full course of either rotavirus vaccine was 72% (95% CI: 56-82) and 71% (95% CI: 50-84) for partial vaccination (one dose of RV1 or one/two doses of RV5). The VE for a complete 3-dose course of RV5 was 82% (95% CI: 59-92) and for a full 2-dose course of RV1 was 73% (95% CI: 55-83). CONCLUSIONS: RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years. Even incomplete courses of vaccination conferred good protection.
引用
- Fathima P, Snelling TL, Gibbs RA, et al. Effectiveness of rotavirus vaccines in an Australian population: A case-control study. Vaccine. 2019. PMID: 31473003. doi:10.1016/j.vaccine.2019.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。